>
Autolus Therapeutics logo

AUTL - Autolus Therapeutics Share Price

$5.29 -0.3  -4.5%

Last Trade - 16/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £269.7m
Enterprise Value £158.8m
Revenue £1.24m
Position in Universe 3867th / 6850
Bullish
Bearish
Unlock AUTL Revenue
Momentum
Relative Strength (%)
1m -28.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -69.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.21 1.69 1.41 0.30 2.91 1.72 0.90 4.60 +7.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AutolusTherapeutics PLC revenues decreased 41% to $1.7M. Net lossincreased 15% to $142.1M. Revenues reflect Grant incomedecrease of 49% to $1.5M. Higher net loss reflects Researchand development - Balancing val increase of 39% to $115.4M(expense), Other income (expense) decrease of 70% to $1.4M(income), lease cost increase of 48% to $6.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AUTL Revenue Unlock AUTL Revenue

Net Income

AUTL Net Income Unlock AUTL Revenue

Normalised EPS

AUTL Normalised EPS Unlock AUTL Revenue

PE Ratio Range

AUTL PE Ratio Range Unlock AUTL Revenue

Dividend Yield Range

AUTL Dividend Yield Range Unlock AUTL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AUTL EPS Forecasts Unlock AUTL Revenue
Profile Summary

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated February 2, 2018
Public Since June 22, 2018
No. of Shareholders: n/a
No. of Employees: 376
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 70,507,309
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AUTL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AUTL
Upcoming Events for AUTL
Frequently Asked Questions for Autolus Therapeutics
What is the Autolus Therapeutics share price?

As of 16/04/21, shares in Autolus Therapeutics are trading at $5.29, giving the company a market capitalisation of £269.7m. This share price information is delayed by 15 minutes.

How has the Autolus Therapeutics share price performed this year?

Shares in Autolus Therapeutics are currently trading at $5.29 and the price has moved by -39.06% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Autolus Therapeutics price has moved by -57.99% over the past year.

What are the analyst and broker recommendations for Autolus Therapeutics?

Of the analysts with advisory recommendations for Autolus Therapeutics, there are there are currently 2 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Autolus Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Autolus Therapeutics next release its financial results?

Autolus Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Autolus Therapeutics dividend yield?

Autolus Therapeutics does not currently pay a dividend.

Does Autolus Therapeutics pay a dividend?

Autolus Therapeutics does not currently pay a dividend.

When does Autolus Therapeutics next pay dividends?

Autolus Therapeutics does not currently pay a dividend.

How do I buy Autolus Therapeutics shares?

To buy shares in Autolus Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Autolus Therapeutics?

Shares in Autolus Therapeutics are currently trading at $5.29, giving the company a market capitalisation of £269.7m.

Where are Autolus Therapeutics shares listed? Where are Autolus Therapeutics shares listed?

Here are the trading details for Autolus Therapeutics:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AUTL
What kind of share is Autolus Therapeutics?

Based on an overall assessment of its quality, value and momentum, Autolus Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Autolus Therapeutics share price forecast 2021?

Shares in Autolus Therapeutics are currently priced at $5.29. At that level they are trading at 0.198% discount to the analyst consensus target price of 0.00.

Analysts covering Autolus Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -2.04 for the next financial year.

How can I tell whether the Autolus Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Autolus Therapeutics. Over the past six months, the relative strength of its shares against the market has been -64.52%. At the current price of $5.29, shares in Autolus Therapeutics are trading at -50.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Autolus Therapeutics PE Ratio?

We were not able to find PE ratio data for Autolus Therapeutics.

Who are the key directors of Autolus Therapeutics?

We were unable to find the directors for Autolus Therapeutics.

Who are the major shareholders of Autolus Therapeutics?

Here are the top five shareholders of Autolus Therapeutics based on the size of their shareholding:

PPF Group N.V. Holding Company
Percentage owned: 20.21% (14.3m shares)
American Funds SMALLCAP World Fund Mutual Fund
Percentage owned: 5.93% (4.18m shares)
Syncona Portfolio Ltd Corporation
Percentage owned: 5.35% (3.78m shares)
Capital World Investors Investment Advisor
Percentage owned: 4.19% (2.96m shares)
Polygon Management Ltd. Investment Advisor
Percentage owned: 3.05% (2.15m shares)
Similar to AUTL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.